Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3103-3110

  Sjöström, Johanna ^a   Blomqvist, Carl ^b   Heikkilä, Päivi ^a   Von Boguslawski, Kristina ^a   Räisänen Sokolowski, Anne ^a   Bengtsson, Nils Olof ^c   Mjaaland, Ingvil ^f   Malmström, Per ^d   Ostenstadt, Björn ^g   Bergh, Jonas ^e   Wist, Erik ^h   Valvere, Vahur ^h   Saksela, Eero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e Center for Digestive Diseases Karolinska   (Sweden)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY KI 67; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH;

EID: 0343517136     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
2. Hickman, J. A. Apoptosis induced by anticancer drugs [Review]. [111 refs]. Cancer Metastasis Rev., 11: 121-139, 1992.
3. Lowe S. W., Ruley H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
4. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
5. el Deiry, W. S. Regulation of p53 downstream genes [Review] [97 refs]. Semin. Cancer Biol., 8: 345-357, 1998.
6. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
7. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases [see comments]. Nature (Lond.)., 366: 701-704, 1993.
8. Attardi, L. D., Lowe, S. W., Brugarolas, J., and Jacks, T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J., 15: 3693-3701, 1996.
9. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 [see comments]. Nature (Lond.), 381: 713-716, 1996.
10. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer therapy [see comments]. Nat. Med., 3: 1034-1036, 1997.
11. Barbareschi, M., Caffo, O., Doglioni, C., Fina, P., Marchetti, A., Buttitta, F., Leek, R., Morelli, L., Leonardi, E., Bevilacqua, G., Dalla, P. P., and Harris, A. L. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer, 74: 208-215, 1996.
12. Diab, S. G., Yu, Y. Y., Hilsenbeck, S. G., Allred, D. C., and Elledge, R. M. WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res. Treat., 43: 99-103, 1997.
13. Rey, M. J., Fernandez, P. L., Jares, P., Munoz, M., Nadal, A., Peiro, N., Nayach, I., Mallofre, C., Muntane, J., Campo, E., Estape, J., and Cardesa, A. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J. Pathol., 184: 265-271, 1998.
14. Shiohara, M., el Deiry, D. W., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
15. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857-860, 1993.
16. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.
17. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
18. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
19. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex understanding tumorigenic mutations [see comments]. Science (Washington DC), 265: 346-355, 1994.
20. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. [Review] [61 refs]. Nature (Lond.), 351: 453-456, 1991.
21. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell., 69: 1237-1245, 1992.
22. McCann, A. H., Kirley, A., Carney, D. N., Corbally, N., Magee, H. M., Keating, G., and Dervan, P. A. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer, 71: 981-985, 1995.
23. Marchetti, A., Buttitta, F., Girlando, S., Dalla, P. P., Pellegrini, S., Fina, P., Doglioni, C., Bevilacqua, G., and Barbareschi, M. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J. Pathol., 175: 31-38, 1995.
24. Sjöström, J., Blomqvist, C., Mouridsen, H., Pluzanska, A., Ottosson Lönn, S., Bengtsson, N. O., Ostenstad, B., Mjaaland, I., Palm-Sjövall, M., Wist, E., Valvere, V., Anderson, H., and Bergh, J. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur. J. Cancer, 35: 1194-1201, 1999.
25. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
26. Masters, J. R., Camplejohn, R. S., Millis, R. R., and Rubens, R. D. Histological grade, elastosis. DNA ploidy and the response to chemotherapy of breast cancer. Br. J. Cancer, 55: 455-457, 1987.
27. Hietanen, P., Blomqvist, C., Wasenius, V-M., Niskanen, E., Franssila, K., and Nordling, S. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br. J. Cancer, 71: 1029-1032, 1995.
28. Remvikos, Y., Mosseri, V., Zajdela, A., Fourquet, A., Durand, J. C., Pouillart, P., and Magdelenat, H. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann. NY Acad. Sci., 698: 193-203, 1993.
29. MacGrogan, G., Mauriac, L., Durand, M., Bonichon, F., Trojani, M., de Mascarel, I., and Coindre, J. M. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST π. Br. J. Cancer, 74: 1458-1465, 1996.
30. Johnson, M. R., Valentine, C., Basilico, C., and Mansukhani, A. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells. Oncogene, 16: 2647-2656, 1998.
31. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
32. Sheikh, M. S., Li, X. S., Chen, J. C., Shao, Z. M., Ordonez, J. V., and Fontana, J. A. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene, 9: 3407-3415, 1994.
33. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A., and El-Houseini, M. E. Induction of p21 (WAF-1/CTP1) during differentiation. Oncogene. 9: 3389-3396, 1994.
34. Wang, J. A., Fan, S., Yuan, R. Q., Ma, Y. X., Meng, Q., Goldberg, I. D., and Rosen, E. M. Ultraviolet radiation down-regulates expression of the cell-cycle inhibitor p21WAF1/CIP1 in human cancer cells independently of p53. Int. J. Radiat. Biol., 75: 301-316, 1999.
35. Elledge, R. M. Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? [Editorial]. J. the Natl. Cancer Inst., 88: 141-143, 1996.
36. Clemons, M., Leahy, M., Valle, J., Jayson, G., Ranson, M., and Howell, A. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur. J. Cancer, 33: 2183-2193, 1997.
37. Ellis, P. A., Lonning, P. E., Borresen, D. A., Aas, T., Geisler, S., Akslen, L. A., Salter, I., Smith, I. E., and Dowsett, M. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br. J. Cancer, 76: 480-485, 1997.
38. 2/M arrest and apoptosis [see comments]. Nat. Med., 2: 72-79, 1996.
39. Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T. J., and Hung, M. C. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell. 2: 581-591, 1998.
40. Zhang, C. C., Yang, J. M., Bash, B. J., White, E., Murphy, M., Levine, A. J., and Hait, W. N. DNA damage increases sensitivity to Vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res., 59: 3663-3670, 1999.
41. Sjöström, J., and Blomqvist, C. Predictive factors for response to cytotoxic treatment in advanced breast cancer [Review]. Acta Oncol., 35 (Suppl. 5). 84-90, 1996.
42. Rozan, S., Vincent, S. A., Zafrani, B., Validire, P., De Cremoux, P., Bernoux, A., Nieruchalski, M., Fourquet, A., Clough, K., Dieras, V., Pouillart, P., and Sastre, G. X. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer, 79: 27-33, 1998.
43. Zambetti, M., Oriana, S., Quattrone, P., Verderio, P., Terenziani, M., Zucali, R., Valagussa, P., and Bonadonna, G. Combined sequential approach in locally advanced breast cancer. Ann. Oncol., 10: 305-310, 1999.
44. Willsher, P. C., Pinder, S. E., Gee, J. M., Ellis, I. O., Chan, S. Y., Nicholson, R. I., Blarney, R. W., and Robertson, J. F. C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res., 18: 3695-3698, 1998.
45. Chevillard, S., Lebeau, J., Pouillart, P., de Toma, C., Beldjord, C., Asselain, B., Klijanienko, J., Fourquet, A., Magdelenat, H., and Vielh, P. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin. Cancer Res., 3: 2471-2478, 1997.
46. Colleoni, M., Orvieto, E., Nole, F., Orlando, L., Minchella, I., Viale, G., Peruzzotti, G., Robertson, C., Noberasco, C., Galimberti, V., Sacchini, V., Veronesi, P., Zurrida, S., Orecchia, R., and Goldhirsch, A. Prediction of response to primary chemotherapy for operable breast cancer. Eur. J. Cancer, 35: 574-579, 1999.
47. Bonetti, A., Zaninelli, M., Leone, R., Cetto, G. L., Pelosi, G., Biolo, S., Menghi, A., Manfrin, E., Bonetti, F., and Piubello, Q. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res., 4: 2331-2336, 1998.
48. Järvinen, T. A., Holli, K., Kuukasjärvi, T., and Isola, J. J. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer, 77: 2267-2273, 1998.
49. Niskanen, E., Franssila, K., Blomqvist, C., Hietanen, P., and Wasenius, V. M. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br. J. Cancer 76: 917-922, 1997.
50. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lönning, P. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.